Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Debora S. Bruno

Hematology Oncology | Oncology
City Of Hope Medical Group Of Georgia LLC
600 Celebrate Life Pkwy, 
Newnan, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Primitive Neuroectodermal Tumor (PNET)
City Of Hope Medical Group Of Georgia LLC
600 Celebrate Life Pkwy, 
Newnan, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Debora Bruno is a Hematologist Oncology specialist and an Oncologist in Newnan, Georgia. Dr. Bruno is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Pleuropulmonary Blastoma. Dr. Bruno is currently accepting new patients.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in NE
Hospital Affiliations
Southeastern Regional Medical Center, Inc
Languages Spoken
English
Portuguese
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF GEORGIA LLC
600 Celebrate Life Pkwy, Newnan, GA 30265

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer
A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Procedure
Study Drugs: Osimertinib, Telaglenastat Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 02, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 3
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 24, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

37 Total Publications

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.
Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.
Journal: Cancer treatment and research
Published: August 23, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Erin Dunbar
Oncology | Hematology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Erin Dunbar
Oncology | Hematology

Piedmont Providers LLC

1984 Peachtree Rd Nw, Suite 300, 
Atlanta, GA 
 (36.1 miles away)
404-367-3210
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erin Dunbar is an Oncologist and a Hematologist in Atlanta, Georgia. Dr. Dunbar is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, and Glioma.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Gena H. Volas-Redd
Hematology Oncology | Hematology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Gena H. Volas-Redd
Hematology Oncology | Hematology | Oncology

Nsh Cancer Institute Professional Services G LLC

790 Church St Ne, Suite 335, 
Marietta, GA 
 (42.2 miles away)
770-590-8311
Languages Spoken:
English, Greek, Spanish
See accepted insurances
Accepting New Patients

Gena Volas-Redd is a Hematologist Oncology specialist and a Hematologist in Marietta, Georgia. Dr. Volas-Redd is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Astrocytoma, and Gliosarcoma. Dr. Volas-Redd is currently accepting new patients.

Byram H. Ozer
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Byram H. Ozer
Hematology Oncology | Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Byram H. Ozer
Hematology Oncology | Hematology | Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (37.6 miles away)
404-778-0519
Experience:
14+ years
Languages Spoken:
English, German
See accepted insurances

Byram Ozer is a Hematologist Oncology specialist and a Hematologist in Atlanta, Georgia. Dr. Ozer has been practicing medicine for over 14 years and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bruno's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile